Last reviewed · How we verify

Pluvicto — Competitive Intelligence Brief

Pluvicto (TETRAXETAN) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radioligand Therapeutic Agent [EPC]. Area: Oncology.

marketed Radioligand Therapeutic Agent [EPC] Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pluvicto (TETRAXETAN) — Novartis. Pluvicto works by binding to the PSMA protein on prostate cancer cells, delivering a radioactive payload to destroy the cancer cells.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pluvicto TARGET TETRAXETAN Novartis marketed Radioligand Therapeutic Agent [EPC] 2025-01-01
Pluvicto Lutetium (177Lu) vipivotide tetraxetan Aaa Usa Novartis marketed Radioligand Therapeutic Agent [EPC] Prostate-specific antigen 2022-01-01
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN marketed Radioligand Therapeutic Agent [EPC] PSMA 2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Radioligand Therapeutic Agent [EPC] class)

  1. · 1 drug in this class
  2. Aaa Usa Novartis · 1 drug in this class
  3. Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pluvicto — Competitive Intelligence Brief. https://druglandscape.com/ci/tetraxetan. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: